Chaves de Jesus Pamela, Rego Rodrigues Silva Deise Maria, Macedo Moura Pedro Henrique, Gopalsamy Rajiv Gandhi, Dias Silva Eloia Emanuelly, Dos Santos Barreto Marina, Santana Santos Ronaldy, Santos Martins Allec Yuri, de Freitas Almeida Anne Gabriela, Santana Corrêa Adriana Kelly, Alves da Mota Santana Lucas, Hariharan Govindasamy, Gibara Guimarães Adriana, Pinto Borges Lysandro
Postgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão 49100-000, Brazil.
Division of Phytochemistry and Drug-Design, Department of Biosciences, Rajagiri College of Social Sciences (Autonomous), Kochi 683104, Kerala, India.
Pharmaceuticals (Basel). 2025 Apr 9;18(4):551. doi: 10.3390/ph18040551.
This review examines in vitro techniques for characterizing the pharmacokinetics of medicinal plants, focusing on their role in understanding absorption, distribution, metabolism, and excretion (ADME). The diverse bioactive compounds in medicinal plants highlight the need for robust pharmacokinetic evaluations to ensure their safety and efficacy. The objectives were to identify and analyze in vitro techniques applied to medicinal plants' pharmacokinetics, addressing a gap in the literature. Studies were included based on predefined eligibility criteria: in vitro pharmacokinetic studies involving medicinal plants, focusing on ADME stages. Ex vivo, in vivo, and in silico studies were excluded, along with reviews. Data were collected from the PubMed, Web of Science, and Scopus databases in June 2024 using Health Sciences Descriptors (DeCS) and their MeSH synonyms. The data extracted included study location, plant species, bioactive compounds, in vitro protocols, and ADME characteristics. The review included 33 studies, with most focusing on metabolism (60%), absorption (25%), or a combination of ADME aspects. Techniques like Caco-2 cells, human liver microsomes, and simulated gastric and intestinal fluids were widely used. The findings highlight methodological heterogeneity, including variability in extract preparation, compound concentrations, and experimental conditions, which limits the comparability and clinical applicability of results. Key limitations include the lack of standardized protocols and physiological relevance in in vitro models, underscoring the need for multidisciplinary approaches and integration with in vivo studies.
本综述探讨了用于表征药用植物药代动力学的体外技术,重点关注其在理解吸收、分布、代谢和排泄(ADME)方面的作用。药用植物中多样的生物活性化合物凸显了进行可靠药代动力学评估以确保其安全性和有效性的必要性。目的是识别和分析应用于药用植物药代动力学的体外技术,以填补文献中的空白。根据预先定义的纳入标准选取研究:涉及药用植物的体外药代动力学研究,重点关注ADME阶段。排除了体外、体内和计算机模拟研究以及综述。2024年6月使用健康科学描述符(DeCS)及其医学主题词表(MeSH)同义词从PubMed、科学网和Scopus数据库收集数据。提取的数据包括研究地点、植物种类、生物活性化合物、体外实验方案和ADME特征。该综述纳入了33项研究,大多数研究聚焦于代谢(60%)、吸收(25%)或ADME各方面的组合。Caco - 2细胞、人肝微粒体以及模拟胃液和肠液等技术被广泛使用。研究结果突出了方法学的异质性,包括提取物制备、化合物浓度和实验条件的变异性,这限制了结果的可比性和临床适用性。主要局限性包括体外模型缺乏标准化方案和生理相关性,强调了多学科方法以及与体内研究相结合的必要性。